Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates

Robert-Guroff, Marjorie; Aldrich, Kristine; Muldoon, Rebecca R.; Stern, Theodore L.; Bansal, Gulshan; Matthews, Thomas J.; Markham, Phillip D.; Gallo, Robert C.; Franchini, Genoveffa

doi:10.1128/jvi.66.6.3602-3608.1992

Cited by 62 publications

(25 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SIV gp120 than the two more rapidly progressing macaques. The V3 region of SIV was originally thought to lack any linear neutralizing epitopes (28,56), unlike the V3 region of HIV, which is a major neutralization site (23,46,50,59). However, weakly neutralizing monoclonal antibodies have been generated against a linear peptide that includes the amino acids of peptide 52 (34), and more recently a synthetic peptide with the sequence MSGLVFHSQPINDRPKQAWC was shown to elicit a broadly reactive neutralizing antibody with a high titer in goats (51).…”

Section: Discussionmentioning

confidence: 99%

Factors Associated with Slow Disease Progression in Macaques Immunized with an Adenovirus-Simian Immunodeficiency Virus (SIV) Envelope Priming-gp120 Boosting Regimen and Challenged Vaginally with SIVmac251

Buge

Murty

Arora

et al. 1999

J Virol

View full text Add to dashboard Cite

Rhesus macaques were immunized with a combination vaccine regimen consisting of adenovirus type 5 host range mutant-simian immunodeficiency virus envelope (Ad5hr-SIVenv) recombinant priming and boosting with native SIV gp120. Upon intravaginal challenge with SIVmac251, both persistently and transiently viremic animals were observed (. 71:8531-8541, 1997). Long-term follow-up of the persistently viremic immunized macaques, which displayed significantly reduced viral burdens during the first 18 weeks postchallenge compared to controls, has now shown that one of four became a slow progressor, clearing virus from plasma and remaining asymptomatic with stable CD4 counts for 134 weeks postchallenge. Reboosting of the transiently viremic macaques did not reactivate latent virus. Rechallenge with two sequential SIVmac251 intravaginal exposures again resulted in partial protection of one of two immunized macaques, manifested by viral clearance and stable CD4 counts. No single immune parameter was associated with partial protection. Development of a strong antibody response capable of neutralizing a primary SIVmac251 isolate together with SIV-specific cytotoxic T lymphocytes were implicated, while CD8 ؉ T-cell antiviral activity and mucosal immune responses were not associated with delayed disease progression. Our data show that even a third immunization with the same Ad5hr-SIVenv recombinant can elicit significant immune responses to the inserted gene product, suggesting that preexisting Ad antibodies may not preclude effective immunization. Further, the partial protection against a virulent, pathogenic SIV challenge observed in two of six macaques immunized with a vaccine regimen based solely on the viral envelope indicates that this vectored-vaccine approach has promise and that multicomponent vaccines based in the same system merit further investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

Factors Associated with Slow Disease Progression in Macaques Immunized with an Adenovirus-Simian Immunodeficiency Virus (SIV) Envelope Priming-gp120 Boosting Regimen and Challenged Vaginally with SIVmac251

Buge

Murty

Arora

et al. 1999

J Virol

View full text Add to dashboard Cite

show abstract

“…An analysis of evolutionary relationships suggests that with regard to the env gene, the HIV-2 group of viruses are more closely related to the SIV group than to the HIV-1 group (16). Also, in contrast to the infrequent cross-neutralization of HIV-1 by HIV-2-or SIV-positive sera, extensive cross-neutralization of HIV-2 or SIV MAC and SIV AGM has been reported (34). Thus, HIV-2 is considered to be more closely related both immunologically and genetically to SIV than to HIV-1.…”

Section: Discussionmentioning

confidence: 99%

“…Uninfected MOLT4 clone 8 (MOLT4C8) cells, CEM cells, and their HIV-and SIV-infected counterparts have been described previously (7,21,28,34). HIV-2 isolates ROD, ISY, and GH1 were kindly provided by L. Montagnier, Pasteur Institute, Paris France, M. Robert-Guroff, National Cancer Institute, Bethesda, Md., and M. Hayami, Kyoto University, Kyoto Japan, re-spectively.…”

Section: Cells and Virusesmentioning

confidence: 99%

“…However, the usefulness of HIV-2/SIV in monkeys as a model for HIV-1 infection of humans has been questioned because of the apparent biological-pathological difference between these virus groups. In particular, the failure or low efficiency of the HIV-2/SIV linear V3-region peptides to induce neutralizing antibodies compared with that of HIV-1 suggests that an additional region(s) of the HIV-2/SIV envelope protein participates in neutralization (34).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120

Matsushita

Matsumi

Yoshimura

et al. 1995

J Virol

View full text Add to dashboard Cite

Monoclonal antibodies (MAbs) were obtained by immunizing mice with synthetic peptides corresponding to the third variable (V3) or the third conserved (C3) domain of the external envelope protein (gp120) of human immunodeficiency virus type 2 (HIV-2 ROD ). One MAb, designated B2C, which was raised against V3 peptide NKI 26, bound to the surface of HIV-2-infected cells but not to their uninfected counterparts. B2C was capable of neutralizing cell-free and cell-associated virus infection in an isolate-specific fashion. The antibody-binding epitope was mapped to a 6-amino-acid peptide in the V3 variable domain which had the core sequence His-Tyr-Gln. Two MAbs, 2H1B and 2F19C, which were raised against the C3 peptide TND27 reacted with gp120 of HIV-2 ROD in a Western immunoblot assay. The C3 epitopes recognized by these two MAbs appeared inaccessible because of their poor reactivity in a surface immunofluorescence assay. Although partial inhibition of syncytium formation was observed in the presence of the anti-C3 MAbs, their neutralizing activity appeared weak. Finally, the effects of these MAbs against CD4-gp120 binding were assessed. Partial inhibition of CD4-gp120 binding was observed in the presence of high concentrations of B2C. On the other hand, no inhibition of CD4-gp120 binding was observed in the presence of anti-C3 MAbs. Since complete neutralization could be achieved at a concentration corresponding to that of partial binding inhibition by B2C, some different mechanisms may be involved in the B2C-mediated neutralization. These results, taken together, indicated that analogous to the function of the V3 region of HIV-1, the V3 region of HIV-2 ROD contained at least a type-specific fusion-inhibiting neutralizing epitope. In this respect, the V3 sequence of HIV-2 may be a useful target in an animal model for HIV vaccine development.

show abstract

“…GP120 with the attachment of virus particles to the target cells, and the gp41 engages in virus-cell fusion (Durham and Chen, 2016;Desai et al, 2015;Dale et al, 2011;Bieniasz et al, 1997;Rausch et al, 1990). While successful in-vitro, recombinant gp120 has failed to generate cross neutralizing antibodies in vivo possibly due to the natural conformation of gp120 (Prevost, 2017;Wang et al, 2016;Doores et al, 2015;Doores et al, 2010;Zhou et al, 2010;Wu et al, 1997;Watkins et al, 1996;Robert-Guroff et al, 1992). Monoclonal antibodies were first generated in mice in 1975 using a hybridoma technique (Patke et al, 2017;Holzlohner and Hanack, 2017;Bhatia et al, 2016;Pogson et al, 2016;Abusneina and Gauthier, 2016;Milstein, 1999), and were subsequently accepted globally by manufacturers.…”

Section: Introductionmentioning

confidence: 99%

Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies

Sun

Yan

Tang³

et al. 2018

Virus Research

View full text Add to dashboard Cite

HIV/AIDS has become a worldwide pandemic. Before an effective HIV-1 vaccine eliciting broadly neutralizing monoclonal antibodies (bnmAbs) is fully developed, passive immunization for prevention and treatment of HIV-1 infection may alleviate the burden caused by the pandemic. Among HIV-1 infected individuals, about 20% of them generated cross-reactive neutralizing antibodies two to four years after infection, the details of which could provide knowledge for effective vaccine design. Recent progress in techniques for isolation of human broadly neutralizing antibodies has facilitated the study of passive immunization. The isolation and characterization of large panels of potent human broadly neutralizing antibodies has revealed new insights into the principles of antibody-mediated neutralization of HIV. In this paper, we review the current effective techniques in broadly neutralizing antibody isolation.

show abstract

Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates

Abstract: In contrast to infrequent and low-titer cross-neutralization of human immunodeficiency virus type 1 (HIV-1) isolates by HIV-2-and simian immunodeficiency virus (SIV)-positive sera, extensive cross-neutralization of * Corresponding author.

Cited by 62 publications

References 40 publications

Factors Associated with Slow Disease Progression in Macaques Immunized with an Adenovirus-Simian Immunodeficiency Virus (SIV) Envelope Priming-gp120 Boosting Regimen and Challenged Vaginally with SIVmac251

Factors Associated with Slow Disease Progression in Macaques Immunized with an Adenovirus-Simian Immunodeficiency Virus (SIV) Envelope Priming-gp120 Boosting Regimen and Challenged Vaginally with SIVmac251

Neutralizing monoclonal antibodies against human immunodeficiency virus type 2 gp120

Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies

Contact Info

Product

Resources

About